MetaVia Inc. (NASDAQ:MTVA) Shares Shorted: Short Interest Down 36.0% in September

MetaVia Inc. (NASDAQ:MTVA) saw a large drop in short interest in the month of September. As of September 30th, there was short interest totaling 117,409 shares, a drop of 36.0% from the September 15th total of 183,472 shares. Currently, 2.3% of the company’s stock are short sold. Based on an average daily volume of 57,790 shares, the days-to-cover ratio is presently 2.0 days.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Wall Street Zen raised MetaVia to a “sell” rating in a research note on Saturday, June 20th. Weiss Ratings reiterated a “sell (e+)” rating on shares of MetaVia in a research note on Tuesday, July 21st. Finally, HC Wainwright reissued a “buy” rating on shares of MetaVia in a research report on Friday, July 10th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $20.00.

MetaVia Trading Up 0.7%

Shares of NASDAQ:MTVA opened at $1.37 on Friday. The stock has a fifty day simple moving average of $1.58 and a two-hundred day simple moving average of $1.66. MetaVia has a 12-month low of $0.97 and a 12-month high of $14.85. The stock has a market capitalization of $7.07 million, a price-to-earnings ratio of -0.42 and a beta of 0.96.

MetaVia (NASDAQ:MTVA) last released its earnings results on Thursday, August 6th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.08). As a group, equities research analysts predict that MetaVia will post -2.79 EPS for the current year.

MetaVia Company Profile

MetaVia, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and other metabolic diseases. The company’s programs are designed to address conditions including excess weight, type 2 diabetes and metabolic dysfunction-associated steatohepatitis (MASH), a form of fatty liver disease associated with metabolic dysfunction.

MetaVia’s pipeline includes DA-1726, an investigational dual GLP-1 and glucagon receptor agonist being developed as a potential treatment for obesity and related metabolic complications.